These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
127 related articles for article (PubMed ID: 19268404)
1. Important pharmacophoric features of pan PPAR agonists: common chemical feature analysis and virtual screening. Sundriyal S; Bharatam PV Eur J Med Chem; 2009 Sep; 44(9):3488-95. PubMed ID: 19268404 [TBL] [Abstract][Full Text] [Related]
3. 'Sum of activities' as dependent parameter: a new CoMFA-based approach for the design of pan PPAR agonists. Sundriyal S; Bharatam PV Eur J Med Chem; 2009 Jan; 44(1):42-53. PubMed ID: 18448203 [TBL] [Abstract][Full Text] [Related]
4. SAR-oriented discovery of peroxisome proliferator-activated receptor pan agonist with a 4-adamantylphenyl group as a hydrophobic tail. Kasuga J; Yamasaki D; Ogura K; Shimizu M; Sato M; Makishima M; Doi T; Hashimoto Y; Miyachi H Bioorg Med Chem Lett; 2008 Feb; 18(3):1110-5. PubMed ID: 18162399 [TBL] [Abstract][Full Text] [Related]
5. Indol-1-yl acetic acids as peroxisome proliferator-activated receptor agonists: design, synthesis, structural biology, and molecular docking studies. Mahindroo N; Wang CC; Liao CC; Huang CF; Lu IL; Lien TW; Peng YH; Huang WJ; Lin YT; Hsu MC; Lin CH; Tsai CH; Hsu JT; Chen X; Lyu PC; Chao YS; Wu SY; Hsieh HP J Med Chem; 2006 Feb; 49(3):1212-6. PubMed ID: 16451087 [TBL] [Abstract][Full Text] [Related]
6. Molecular recognition of docosahexaenoic acid by peroxisome proliferator-activated receptors and retinoid-X receptor alpha. Gani OA; Sylte I J Mol Graph Model; 2008 Sep; 27(2):217-24. PubMed ID: 18547851 [TBL] [Abstract][Full Text] [Related]
7. Structural basis for the structure-activity relationships of peroxisome proliferator-activated receptor agonists. Mahindroo N; Peng YH; Lin CH; Tan UK; Prakash E; Lien TW; Lu IL; Lee HJ; Hsu JT; Chen X; Liao CC; Lyu PC; Chao YS; Wu SY; Hsieh HP J Med Chem; 2006 Oct; 49(21):6421-4. PubMed ID: 17034149 [TBL] [Abstract][Full Text] [Related]
9. 3D-pharmacophore models for selective A2A and A2B adenosine receptor antagonists. Wei J; Wang S; Gao S; Dai X; Gao Q J Chem Inf Model; 2007; 47(2):613-25. PubMed ID: 17330954 [TBL] [Abstract][Full Text] [Related]
10. Structure-activity relationships and key structural feature of pyridyloxybenzene-acylsulfonamides as new, potent, and selective peroxisome proliferator-activated receptor (PPAR) γ Agonists. Rikimaru K; Wakabayashi T; Abe H; Tawaraishi T; Imoto H; Yonemori J; Hirose H; Murase K; Matsuo T; Matsumoto M; Nomura C; Tsuge H; Arimura N; Kawakami K; Sakamoto J; Funami M; Mol CD; Snell GP; Bragstad KA; Sang BC; Dougan DR; Tanaka T; Katayama N; Horiguchi Y; Momose Y Bioorg Med Chem; 2012 May; 20(10):3332-58. PubMed ID: 22503460 [TBL] [Abstract][Full Text] [Related]
11. Investigation of potential glycogen synthase kinase 3 inhibitors using pharmacophore mapping and virtual screening. Dessalew N; Bharatam PV Chem Biol Drug Des; 2006 Sep; 68(3):154-65. PubMed ID: 17062013 [TBL] [Abstract][Full Text] [Related]
12. Discovery of potential ZAP-70 kinase inhibitors: pharmacophore design, database screening and docking studies. Sanam R; Vadivelan S; Tajne S; Narasu L; Rambabu G; Jagarlapudi SA Eur J Med Chem; 2009 Dec; 44(12):4793-800. PubMed ID: 19674816 [TBL] [Abstract][Full Text] [Related]
13. Identification of novel serotonin 2C receptor ligands by sequential virtual screening. Ahmed A; Choo H; Cho YS; Park WK; Pae AN Bioorg Med Chem; 2009 Jul; 17(13):4559-68. PubMed ID: 19464901 [TBL] [Abstract][Full Text] [Related]
14. Virtual screening for PPAR modulators using a probabilistic neural network. Derksen S; Rau O; Schneider P; Schubert-Zsilavecz M; Schneider G ChemMedChem; 2006 Dec; 1(12):1346-50. PubMed ID: 17066499 [No Abstract] [Full Text] [Related]
15. Improvement of the transactivation activity of phenylpropanoic acid-type peroxisome proliferator-activated receptor pan agonists: effect of introduction of fluorine at the linker part. Kasuga J; Oyama T; Hirakawa Y; Makishima M; Morikawa K; Hashimoto Y; Miyachi H Bioorg Med Chem Lett; 2008 Aug; 18(16):4525-8. PubMed ID: 18662876 [TBL] [Abstract][Full Text] [Related]
16. Selective pharmacophore models of dopamine D(1) and D(2) full agonists based on extended pharmacophore features. Malo M; Brive L; Luthman K; Svensson P ChemMedChem; 2010 Feb; 5(2):232-46. PubMed ID: 20077461 [TBL] [Abstract][Full Text] [Related]
17. Consensus scoring with feature selection for structure-based virtual screening. Teramoto R; Fukunishi H J Chem Inf Model; 2008 Feb; 48(2):288-95. PubMed ID: 18229906 [TBL] [Abstract][Full Text] [Related]
18. Modulation of PPAR receptor subtype selectivity of the ligands: aliphatic chain vs aromatic ring as a spacer between pharmacophore and the lipophilic moiety. Pingali H; Jain M; Shah S; Patil P; Makadia P; Zaware P; Sairam KV; Jamili J; Goel A; Patel M; Patel P Bioorg Med Chem Lett; 2008 Dec; 18(24):6471-5. PubMed ID: 18976908 [TBL] [Abstract][Full Text] [Related]
19. Discovery of novel PPAR ligands by a virtual screening approach based on pharmacophore modeling, 3D shape, and electrostatic similarity screening. Markt P; Petersen RK; Flindt EN; Kristiansen K; Kirchmair J; Spitzer G; Distinto S; Schuster D; Wolber G; Laggner C; Langer T J Med Chem; 2008 Oct; 51(20):6303-17. PubMed ID: 18821746 [TBL] [Abstract][Full Text] [Related]
20. Knowledge based identification of MAO-B selective inhibitors using pharmacophore and structure based virtual screening models. Boppana K; Dubey PK; Jagarlapudi SA; Vadivelan S; Rambabu G Eur J Med Chem; 2009 Sep; 44(9):3584-90. PubMed ID: 19321235 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]